首页> 美国卫生研究院文献>The British Journal of Ophthalmology >Clinical experience of e-PTFE membrane implant surgery for refractory glaucoma
【2h】

Clinical experience of e-PTFE membrane implant surgery for refractory glaucoma

机译:e-PTFE膜植入手术治疗难治性青光眼的临床经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Aims: To evaluate the clinical efficacy of membrane tube implant made of expanded polytetrafluoroethylene (e-PTFE, Gore-Tex) membrane and silicone tube in treating refractory glaucoma.>Methods: A retrospective chart review was performed on 43 eyes of 40 patients who underwent glaucoma tube shunt implant surgery using double layered e-PTFE membrane and silicone tube to treat refractory glaucoma. The surgeries were performed from May 1991 to September 1995, and the subjects were patients with terminal glaucoma without useful vision on the study eye.>Results: The mean follow up period was 32.9 months. The Kaplan-Meier survival for intraocular pressure (IOP) control (IOP between 6 and 21mm Hg without significant complication) was 80.9% at 1 year, 73.9% at 2 years, and 62.2% at 3 years after surgery. After excluding three eyes of three patients who were dropped within 3 months after surgery and did not have any serious complication or problem in IOP control, the average preoperative IOP was 42.5 (SD 14.6) mm Hg and IOP on the last visit was 17.3 (10.2) mm Hg (p = 0.000, n = 40). The number of antiglaucoma medications before surgery (2.2 (0.6)) was reduced to 0.5 (0.8) on the last visit (p = 0.000). The IOP was controlled within the range of 6–21 mm Hg in 26 eyes (65.0%). In the remaining 14 eyes (35%), we could not control the IOP or additional surgery was needed to control the IOP or to treat severe complications. Two cases of endophthalmitis and three of phthisis were found as serious complications. The other complications were similar to those of other commercially available glaucoma implants.>Conclusion: A comparable clinical result was obtained with this new implant as with the other commercially available implants. This implant with a thin and non-rigid reservoir has a potential to reduce some complications associated with the large volume and rigid consistency of the other implants, although it is not yet proved. This membrane tube implant may be considered as another substitute in the surgery of refractory glaucoma.
机译:>目的:评价由膨体聚四氟乙烯(e-PTFE,Gore-Tex)膜和硅胶管制成的膜管植入物治疗难治性青光眼的临床疗效。>方法:回顾性图表回顾了40例接受青光眼分流植入手术的患者的43眼,使用双层e-PTFE膜和硅胶管治疗难治性青光眼。手术时间为1991年5月至1995年9月,对象为研究眼中无有效视力的终末期青光眼患者。>结果:平均随访时间为32.9个月。眼内压(IOP)控制(IOP在6至21mm Hg之间,无明显并发症)的Kaplan-Meier存活率在术后1年时为80.9%,在2年时为73.9%,在3年时为62.2%。排除3例在术后3个月内滴眼且无严重并发症或IOP控制问题的患者的三只眼后,术前平均IOP为42.5(SD 14.6)mm Hg,上次就诊的IOP为17.3(10.2) )毫米汞柱(p = 0.000,n = 40)。上次就诊时,手术前抗青光眼药物的数量(2.2(0.6))减少到0.5(0.8)(p = 0.000)。 26只眼的IOP控制在6-21 mm Hg的范围内(65.0%)。在剩下的14眼(35%)中,我们无法控制IOP,或者需要额外的手术来控制IOP或治疗严重并发症。发现2例眼内炎和3例咽部炎为严重并发症。其他并发症与其他市售青光眼植入物相似。>结论:与其他市售植入物相比,这种新植入物获得了可比的临床结果。尽管还没有得到证实,但这种具有薄且非刚性储层的植入物具有减少与其他植入物的大体积和刚性一致性相关的一些并发症的潜力。这种膜管植入物可以被认为是难治性青光眼手术的另一种替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号